Urine preserving fluid, method for preserving urine and application of urine preserving fluid

By adding imidazolidinyl urea, sodium azide, sulfite and spermine to the urine preservation solution, the proliferation of microorganisms and nucleic acid degradation in the urine is suppressed, and the problems in the preservation and transportation of urine samples are solved. Improves detection accuracy and sensitivity and simplifies operational procedures.

CN118932018APending Publication Date: 2024-11-12PEKING UNIVERSITY FIRST HOSPITAL (PEKING UNIVERSITY FIRST CLINICAL MEDICAL COLLEGE) +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411011986.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art can easily lead to microbial proliferation and nucleic acid degradation during the preservation and transportation of urine samples, affecting the detection results. Especially when primary hospitals lack testing conditions, how to effectively preserve and transport urine samples has become a problem.

Method used

Microbial proliferation is inhibited by adding imidazolidinylurea and sodium azide to the urine preservation solution, and the use of sulfite and spermidine to reduce the inhibitory effect of substances on nucleic acid amplification, combining diethyl pyrocarbonate and ethylenediamine Tetraacetic acid inhibits the activity of RNase and DNA enzymes and improves the detection accuracy of urine samples.

Benefits of technology

It effectively inhibits the growth of microorganisms and the degradation of nucleic acids in the urine, reduces the probability of false positive and false negative results, improves the detection accuracy of urine samples, and reduces the sample volume through centrifugal concentration, which is easy to transport and simple and economical to operate.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118932018A_ABST
    Figure CN118932018A_ABST
Patent Text Reader

Abstract

The invention relates to a urine preservation solution, a urine preservation method and application thereof, and the urine preservation solution comprises the following components in percentage by mass: 0.01-0.1% of diethyl pyrocarbonate, 3-7% of ethylenediamine tetraacetic acid, 1-5% of imidazolidinyl urea, 2-5% of sulfite, 1-5% of sodium azide, 0.5-2.5% of spermidine and the balance of water. The imidazolidinyl urea and the sodium azide are added into the urine preservation solution to synergistically inhibit proliferation of microorganisms in urine, and the sulfite and the spermidine are added to synergistically reduce the influence of substances in the urine on nucleic acid amplification, so that the detection accuracy of the microorganisms in a urine sample is improved, and the probability of occurrence of false positive and false negative results is reduced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of nucleic acid detection, and in particular to a urine preserving solution, a method for preserving urine and applications thereof. Background Art

[0002] Urinary tract infection (UTI) is one of the most common community-acquired and hospital-acquired infections. More than 50% of women experience at least one UTI in their lifetime, and up to 25% of female patients who have had UTI will experience recurrence in their daily lives. Currently, the main means of diagnosing and treating UTI still relies on the results of urine culture, but this method takes at least 42-78 hours from pathogen identification to drug sensitivity testing, and clinical workers can obtain pathogenic bacteria and their drug sensitivity results in an average of 3 days. In recent years, molecular biology technology has been used to detect pathogenic microorganisms at the nucleic acid level, which has not only greatly improved the detection range and accuracy, but also provided drug-resistant gene detection results to a certain extent, and greatly shortened the detection time.

[0003] CN110596370A discloses an enzyme-linked immunosorbent assay kit for detecting bacterial urinary tract infection and its application. Experiments have found that in in vitro and in vivo models of urinary tract infection, the expression of S100A6 protein in cells after bacterial infection is significantly increased, and the expression of S100A6 in mouse bladder tissue is also upregulated. Therefore, the S100A6 content in urine samples can be used to determine whether an individual has the possibility of bacterial urinary tract infection or the tendency to urinary tract infection.

[0004] CN105969854A discloses a gene chip kit for detecting pathogenic bacteria of urinary tract infection and a detection method thereof, comprising a gene chip and a detection system for detection, wherein the gene chip comprises a working electrode, a reference electrode and an auxiliary electrode, the working electrode is marked with a capture probe, and the detection system comprises mutually independent DNA extraction solution, PCR amplification reaction solution, PCR product enzyme solution, hybridization solution, detection solution, blank control, positive quality control product and negative quality control product.

[0005] The above technologies all test urine in real time. When primary hospitals do not have the conditions for testing and need to transfer samples to be tested, how to preserve urine samples is a crucial issue. Inappropriate transportation and storage conditions can easily cause the proliferation of microorganisms in urine and the degradation of pathogenic microorganism nucleic acids, affecting the test results and further affecting clinical treatment. Because the pathogen load in urine is low, a relatively large amount of sample is required to improve the detection efficiency, but a large amount of urine is not easy to store and transport.

[0006] In summary, how to preserve urine samples and improve the sensitivity of urine sample detection has become one of the urgent problems to be solved in this field. Summary of the invention

[0007] In order to solve the above technical problems, the present invention provides a urine preservative solution, a method for preserving urine and applications thereof. The present invention adds imidazolidinyl urea and sodium azide to the urine preservative solution to synergistically inhibit the proliferation of microorganisms in urine, and adds sulfite and spermidine to synergistically reduce the effects of substances in urine on nucleic acid amplification, thereby improving the accuracy of microbial detection in urine samples and reducing the probability of false positive and false negative results.

[0008] To achieve this object, the present invention adopts the following technical solutions:

[0009] In the first aspect, the present invention provides a urine preservation solution, which, based on the mass percentage of 100%, includes 0.01%-0.1% diethyl pyrocarbonate, 3%-7% ethylenediaminetetraacetic acid, 1%-5% imidazolidinyl urea, 2%-5% sulfite, 1%-5% sodium azide and 0.5%-2.5% spermidine, and the balance is water.

[0010] The urine preservation solution provided by the present invention can reduce the influence of human components in urine on the detection of pathogenic components in urine, inhibit the growth of pathogenic microorganisms, prevent the degradation of free nucleic acids, and reduce the influence of inhibitory components in urine on nucleic acid amplification, thereby reducing the probability of false positive and false negative results in subsequent pathogenic microbiological detection.

[0011] The invention uses imidazolidinyl urea and sodium azide to synergistically inhibit the proliferation of microorganisms in urine, uses sulfite and spermidine to synergistically eliminate the inhibitory effect of substances other than nucleic acids in urine on nucleic acid amplification, and promotes nucleic acid amplification; uses diethyl pyrocarbonate as an RNase inhibitor, denatures the protein by combining with the imidazole ring of histidine, an active group of RNase, thereby inhibiting the degradation of RNA by RNase; uses ethylenediaminetetraacetic acid as a DNase inhibitor, complexes metal ions in the sample, and inhibits the degradation of nucleic acid by nuclease.

[0012] The specific point values ​​of the above 0.01%-0.1% may be selected from 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09% or 0.1%, etc.

[0013] The specific point values ​​of the above 3%-7% may be 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5% or 7%, etc.

[0014] The specific point values ​​of the above 1%-5% may be 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5% or 5%, etc.

[0015] The specific point values ​​of the above 2%-5% may be 2%, 2.5%, 3%, 3.5%, 4%, 4.5% or 5% etc.

[0016] The specific point values ​​of the above 0.5%-2.5% may be 0.5%, 0.75%, 1%, 1.25%, 1.5%, 1.75%, 2%, 2.25% or 2.5%, etc.

[0017] In a second aspect, the present invention provides use of the urine preservation solution as described in the first aspect in inhibiting microbial growth and / or nucleic acid degradation in urine.

[0018] In a third aspect, the present invention provides a method for preserving urine, comprising concentrating the urine to be tested to obtain a precipitate, and mixing the precipitate with the urine preserving solution described in the first aspect to obtain a mixed solution.

[0019] Preferably, the concentration comprises subjecting the urine to be tested to a first centrifugation, taking the supernatant and subjecting it to a second centrifugation, and retaining the precipitate.

[0020] The present invention reduces the volume of urine by centrifugal concentration to facilitate the transportation of samples. Human cell precipitates are first removed by low-speed centrifugation, and then the precipitates are obtained by high-speed centrifugation. Finally, urine preservation fluid is added. The operation method is simple and quick, and does not require expensive instruments and equipment. It is economical and practical, and has broad application prospects in the preservation and transportation of urine.

[0021] Preferably, the first centrifugation time is 1-5 min, and the first centrifugation speed is 1000-2000 r / min.

[0022] The specific point values ​​of the above 1-5 minutes can be selected from 1 minute, 2 minutes, 3 minutes, 4 minutes or 5 minutes, etc.

[0023] The specific point values ​​of the above-mentioned 1000-2000r / min can be selected as 1000r / min, 1100r / min, 1200r / min, 1300r / min, 1400r / min, 1500r / min, 1600r / min, 1700r / min, 1800r / min, 1900r / min or 2000r / min, etc.

[0024] Preferably, the second centrifugation time is 5-15 min, and the second centrifugation speed is 10000-20000 r / min.

[0025] The specific point values ​​of 5-15min mentioned above can be selected from 5min, 6min, 7min, 8min, 9min, 10min, 11min, 12min, 13min, 14min or 15min, etc.

[0026] The specific point values ​​of the above-mentioned 10000-20000r / min can be selected as 10000r / min, 11000r / min, 12000r / min, 13000r / min, 14000r / min, 15000r / min, 16000r / min, 17000r / min, 18000r / min, 19000r / min or 20000r / min, etc.

[0027] Preferably, the volume ratio of the precipitate to the urine to be tested is 1:(5-15).

[0028] The specific point values ​​of the above (5-15) can be selected from 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15, etc.

[0029] Preferably, the volume ratio of the precipitate to the urine preservation solution during the mixing is 1:(3-7).

[0030] The specific point values ​​of (3-7) above can be selected from 3, 4, 5, 6 or 7, etc.

[0031] Preferably, the mixing further comprises the steps of shaking and mixing and resuspending the precipitate.

[0032] Preferably, the storage temperature of the mixed solution is 0-8°C.

[0033] The specific point values ​​of 0-8°C mentioned above can be selected from 0°C, 1°C, 2°C, 3°C, 4°C, 5°C, 6°C, 7°C or 8°C, etc.

[0034] Preferably, the method for preserving urine comprises the following steps:

[0035] (1) centrifuging the urine to be tested at 1000-2000 r / min for 1-5 min, taking the supernatant and centrifuging at 10000-20000 r / min for 5-15 min, retaining the precipitate, wherein the volume ratio of the precipitate to the urine to be tested is 1:(5-15);

[0036] (2) Mixing the precipitate with the urine preservation solution described in the first aspect, wherein the volume ratio of the precipitate to the urine preservation solution is 1:(3-7), shaking and mixing, resuspending the precipitate, obtaining a mixed solution, and storing it at 0-8°C.

[0037] The specific point values ​​of the above-mentioned 1000-2000r / min can be selected as 1000r / min, 1100r / min, 1200r / min, 1300r / min, 1400r / min, 1500r / min, 1600r / min, 1700r / min, 1800r / min, 1900r / min or 2000r / min, etc.

[0038] The specific point values ​​of the above 1-5 minutes can be selected from 1 minute, 2 minutes, 3 minutes, 4 minutes or 5 minutes, etc.

[0039] The specific point values ​​of the above-mentioned 10000-20000r / min can be selected as 10000r / min, 11000r / min, 12000r / min, 13000r / min, 14000r / min, 15000r / min, 16000r / min, 17000r / min, 18000r / min, 19000r / min or 20000r / min, etc.

[0040] The specific point values ​​of 5-15min mentioned above can be selected from 5min, 6min, 7min, 8min, 9min, 10min, 11min, 12min, 13min, 14min or 15min, etc.

[0041] The specific point values ​​of the above (5-15) can be selected from 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15, etc.

[0042] The specific point values ​​of (3-7) above can be selected from 3, 4, 5, 6 or 7, etc.

[0043] The specific point values ​​of 0-8°C mentioned above can be selected from 0°C, 1°C, 2°C, 3°C, 4°C, 5°C, 6°C, 7°C or 8°C, etc.

[0044] In a fourth aspect, the present invention provides the use of the urine preservation solution as described in the first aspect or the method for preserving urine as described in the third aspect in the detection of urine microbial content.

[0045] Other specific point values ​​within the above numerical ranges can be selected and will not be described in detail here.

[0046] Compared with the prior art, the present invention has the following beneficial effects:

[0047] (1) The present invention provides a urine preservation solution, wherein imidazolidinyl urea and sodium azide synergistically inhibit the proliferation of microorganisms in urine, and sulfite and spermidine synergistically reduce the effect of substances in urine on nucleic acid amplification, thereby improving the accuracy of microbial detection in urine samples and reducing the probability of false positives and false negatives;

[0048] (2) The present invention provides a method for preserving urine, which removes impurities by centrifuging at a low speed followed by a high speed centrifugation, while reducing the volume of urine for easy transportation. The operation method is simple and quick, and does not require expensive instruments and equipment. It is economical and practical, and has broad application prospects in the preservation and transportation of urine. BRIEF DESCRIPTION OF THE DRAWINGS

[0049] Figure 1 This is a graph showing the effects of different pre-treatments and storage times on pathogen detection;

[0050] Figure 2 The results of the effects of different pre-treatment and storage time on the relative abundance of 16S

[0051] Figure 3 This graph shows the effects of different pre-treatment and storage times on human DNA detection. DETAILED DESCRIPTION

[0052] To further illustrate the technical means and effects of the present invention, the present invention is further described below in conjunction with the embodiments and drawings. It should be understood that the specific implementation methods described herein are only used to explain the present invention, rather than to limit the present invention.

[0053] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.

[0054] Preparation Example 1

[0055] In this preparation example, a urine preservation solution is prepared. Based on the mass percentage of 100%, the urine preservation solution includes 0.05% diethyl pyrocarbonate, 5% ethylenediaminetetraacetic acid, 3% imidazolidinyl urea, 3.5% sulfite, 2.5% sodium azide and 1.5% spermidine, and the balance is water.

[0056] Preparation Example 2

[0057] In this preparation example, a urine preservation solution is prepared. Based on the mass percentage of 100%, the urine preservation solution includes 0.01% diethyl pyrocarbonate, 7% ethylenediaminetetraacetic acid, 1% imidazolidinyl urea, 5% sulfite, 1% sodium azide and 2.5% spermidine, and the balance is water.

[0058] Preparation Example 3

[0059] In this preparation example, a urine preservation solution is prepared. Based on the mass percentage of 100%, the urine preservation solution includes 0.1% diethyl pyrocarbonate, 3% ethylenediaminetetraacetic acid, 5% imidazolidinyl urea, 2% sulfite, 5% sodium azide and 0.5% spermidine, and the balance is water.

[0060] Comparative Preparation Example 1

[0061] This comparative preparation example prepares a urine preservation solution, which differs from Preparation Example 1 only in that imidazolidinyl urea is missing and the mass fraction of imidazolidinyl urea is allocated to sodium azide.

[0062] Comparative Preparation Example 2

[0063] This comparative preparation example prepares a urine preservation solution, which differs from Preparation Example 1 only in that sodium azide is missing and the mass share of sodium azide is allocated to imidazolidinyl urea.

[0064] Comparative Preparation Example 3

[0065] This comparative preparation example prepared a urine preservation solution, which differed from Preparation Example 1 only in that the imidazolidinyl urea was replaced with formalin of the same mass.

[0066] Comparative Preparation Example 4

[0067] This comparative preparation example prepared a urine preservation solution, which differed from Preparation Example 1 only in that sodium azide was replaced with sodium borate of the same mass.

[0068] Comparative Preparation Example 5

[0069] This comparative preparation example prepares a urine preservation solution, which differs from Preparation Example 1 only in that sulfite is absent and the mass fraction of sulfite is allocated to spermidine.

[0070] Comparative Preparation Example 6

[0071] This comparative preparation example prepared a urine preservation solution, which differs from Preparation Example 1 only in that spermidine is absent and the mass fraction of spermidine is allocated to sulfite.

[0072] Comparative Preparation Example 7

[0073] This comparative preparation example prepared a urine preservation solution, which differed from Preparation Example 1 only in that sulfite was replaced by allantoin of the same mass.

[0074] Comparative Preparation Example 8

[0075] This comparative preparation example prepared a urine preservation solution, which differed from Preparation Example 1 only in that spermidine was replaced with trehalose of the same mass.

[0076] Example 1

[0077] This embodiment provides a method for preserving urine, and the method for preserving urine comprises the following steps:

[0078] (1) Centrifuging the urine to be tested at 1500 r / min for 3 min, taking the supernatant and centrifuging at 13000 r / min for 10 min, retaining the precipitate, wherein the volume ratio of the precipitate to the urine to be tested is 1:10;

[0079] (2) Mix the precipitate with urine preservation solution, wherein the volume ratio of the precipitate to the urine preservation solution is 1:5, shake and mix, resuspend the precipitate, obtain a mixed solution, and store it at 4°C.

[0080] Example 2

[0081] This embodiment provides a method for preserving urine, and the method for preserving urine comprises the following steps:

[0082] (1) Centrifuging the urine to be tested at 2000 r / min for 1 min, taking the supernatant and centrifuging at 20000 r / min for 5 min, retaining the precipitate, wherein the volume ratio of the precipitate to the urine to be tested is 1:5;

[0083] (2) Mix the precipitate with urine preservation solution, wherein the volume ratio of the precipitate to the urine preservation solution is 1:7, shake and mix, resuspend the precipitate, obtain a mixed solution, and store it at 0°C.

[0084] Example 3

[0085] This embodiment provides a method for preserving urine, and the method for preserving urine comprises the following steps:

[0086] (1) Centrifuging the urine to be tested at 1000 r / min for 5 min, taking the supernatant and centrifuging at 10000 r / min for 15 min, retaining the precipitate, wherein the volume ratio of the precipitate to the urine to be tested is 1:15;

[0087] (2) Mix the precipitate with urine preservation solution, wherein the volume ratio of the precipitate to the urine preservation solution is 1:3, shake and mix, resuspend the precipitate, obtain a mixed solution, and store it at 8°C.

[0088] Example 4

[0089] This embodiment provides a method for preserving urine, which is different from Embodiment 1 only in that the rotation speed of the first centrifugation in step (1) is 800 r / min.

[0090] Example 5

[0091] This embodiment provides a method for preserving urine, which is different from Embodiment 1 only in that the rotation speed of the first centrifugation in step (1) is 2200 r / min.

[0092] Example 6

[0093] This embodiment provides a method for preserving urine, which differs from Embodiment 1 only in that the rotation speed of the second centrifugation in step (1) is 8000 r / min.

[0094] Example 7

[0095] This embodiment provides a method for preserving urine, which differs from Embodiment 1 only in that the rotation speed of the second centrifugation in step (1) is 22000 r / min.

[0096] Example 8

[0097] This embodiment provides a method for preserving urine, which is different from Embodiment 1 only in that step (1) does not perform a low-speed centrifugation process, but directly centrifuges the urine to be tested at 13000 r / min for 10 min to retain the precipitate.

[0098] Application Example 1

[0099] In this application example, the urine to be tested is concentrated and preserved using the method provided in Example 1, wherein the urine preservation solution in step (2) is the urine preservation solution prepared in Preparation Example 1.

[0100] Application Example 2-8

[0101] This application example concentrates and preserves the urine to be tested, and the only difference from application example 1 is that the method provided in examples 2-8 is used.

[0102] Application Examples 9-10

[0103] In this application example, the urine to be tested is concentrated and preserved. The only difference from application example 1 is that the urine preservation solution is the urine preservation solution prepared in preparation example 2-3.

[0104] Comparative Application Examples 1-8

[0105] In this comparative application example, the urine to be tested is concentrated and preserved. The only difference from application example 1 is that the urine preservation solution is the urine preservation solution prepared in comparative preparation examples 1-8.

[0106] Test Example 1

[0107] This test example tests the urine sample stored in Example 1, including the following steps:

[0108] 1. Preparation of urine:

[0109] (1) Urine of the control group:

[0110] a. Divide the urine samples of 4 cases with known results into 600 μL / tube;

[0111] b. The urine was stored at 4°C for 0, 3, and 7 days, and then subjected to subsequent pathogen targeted sequencing (tNGS) and 16S amplicon sequencing.

[0112] (2) Urine of the experimental group:

[0113] 5 mL of urine from 4 samples with known results similar to those of the control group was stored according to Application Example 1 and stored at 4°C for 0, 3, and 7 days before subsequent tNGS testing and 16S amplicon sequencing.

[0114] 2. Nucleic acid extraction:

[0115] Nucleic acid extraction and purification kits were used to extract and purify nucleic acids from urine samples.

[0116] 3. tNGS testing:

[0117] (1) Design primers for target pathogens and human DNA, and use multiplex amplification enzymes to perform multiplex PCR amplification to enrich specific nucleic acid fragments of common pathogens and human DNA in urine. The amplification procedure is shown in Table 1;

[0118] Table 1

[0119]

[0120] (2) purifying the nucleic acid of the PCR product using a magnetic bead separation method;

[0121] (3) After the purified nucleic acid is added to the sequencing adapter sequence, PCR amplification is performed again. The amplification program is shown in Table 2:

[0122] Table 2

[0123]

[0124] (4) The PCR product is purified, the concentration of the purified nucleic acid is measured by a nucleic acid quantifier, and each sample nucleic acid is mixed at a volume of 60 ng to serve as a sequencing library.

[0125] (5) The sequencing library was denatured with 0.1 mol / L sodium hydroxide for 5 min and then sequenced at a volume of 1 pmol.

[0126] 4. 16S amplicon sequencing:

[0127] (1) Select 16S V3-V4 amplification primers 341F and 805R for amplification to enrich the 16S V3-V4 fragments of microorganisms in urine. The amplification procedure is shown in Table 3;

[0128] Table 3

[0129]

[0130] (2) purifying the nucleic acid of the PCR product using a magnetic bead separation method;

[0131] (3) After the purified nucleic acid is added to the sequencing adapter sequence, PCR amplification is performed again. The amplification program is shown in Table 4:

[0132] Table 4

[0133]

[0134] (4) Purify the PCR product, measure the concentration and length distribution of the purified library, and perform absolute quantification of the library.

[0135] (5) The library was sequenced by Miseq PE300.

[0136] 5. Results

[0137] tNGS detection was used to compare the pathogen detection RPK (normalized sequence number) and human detection RPK after different pre-treatment and storage time. 16S amplicon sequencing was used to compare the relative abundance of 16S after different pre-treatment and storage time.

[0138] like Figure 1 As shown, the detection value of microorganisms in the experimental group was higher than that in the control group, indicating that the present invention improved the efficiency of amplification and the sensitivity of detection by adding urine preservation solution; at the same time, after being stored at 4°C for 7 days, the microorganisms in the urine of the experimental group did not proliferate, while the microorganisms in the control group proliferated significantly, and the detection value increased with time.

[0139] like Figure 2 As shown, as the storage time increases, the relative abundance of 16S in the control group microorganisms fluctuates greatly, while the relative abundance of 16S in the experimental group microorganisms fluctuates less. In summary, it is shown that the present invention inhibits microbial proliferation by adding urine preservation solution and improves the stability of the test results.

[0140] like Figure 3 As shown, the amount of human DNA detected in the experimental group was less than that in the control group, indicating that the present invention removes human substances in urine through a specific method of preserving urine, thereby reducing the impact of human nucleic acid on detection.

[0141] Test Example 2

[0142] This test example tests the urine samples stored in Example 1-10 and Comparative Application Example 1-8, including the following steps:

[0143] Urine samples known to contain Enterococcus faecalis, Staphylococcus epidermidis, and Staphylococcus haemolyticus were stored according to Application Examples 1-10 and Comparative Application Examples 1-8, and subsequent tNGS tests were performed after 0 days, 3 days, and 7 days of storage. Nucleic acid extraction, library construction, sequencing, and result processing were performed according to Test Example 1, and the results are shown in Table 5.

[0144] Table 5

[0145]

[0146] From Table 3, we can conclude that:

[0147] (1) Comparing Application Example 1 with Application Examples 4 and 5, it can be seen that if the first centrifugal speed is too low, more human cells cannot be removed, resulting in a low RPK for pathogen detection; if the first centrifugal speed is too high, a small part of pathogenic microorganisms will be removed, resulting in a low RPK for pathogen detection;

[0148] (2) Comparing Application Example 1 with Application Examples 6 and 7, it can be seen that if the second centrifugal speed is too low, the pathogenic microorganisms cannot be completely precipitated, resulting in a low RPK for pathogen detection; if the second centrifugal speed is too high, some pathogenic microorganism cells will rupture, resulting in a low RPK for pathogen detection;

[0149] (3) Comparing Application Example 1 with Application Example 8, it can be seen that only one centrifugation cannot remove impurities in human cells and urine, resulting in a low RPK for pathogen detection;

[0150] (4) Comparison of Application Example 1 with Comparative Application Examples 1-4 shows that imidazolidinyl urea and sodium azide synergistically inhibit the proliferation of microorganisms in urine. Removing one or replacing one will affect the antibacterial effect of urine preservation solution and increase the standard deviation.

[0151] (5) Comparing Application Example 1 with Comparative Application Examples 5-8, it can be seen that sulfite and spermidine synergistically promote nucleic acid amplification, and removing or replacing one of them will reduce the detection result.

[0152] In summary, the present invention provides a urine preservation solution, wherein imidazolidinyl urea and sodium azide synergistically inhibit the proliferation of microorganisms in urine, the relative abundance of microorganism 16S fluctuates less, and sulfite and spermidine synergistically reduce the effect of substances in urine on nucleic acid amplification, thereby improving the accuracy of microbial detection in urine samples and reducing the probability of false positive and false negative results. The present invention also provides a method for preserving urine, which removes impurities by centrifugation at low speed followed by high speed, while reducing the volume of urine for easy transportation. The operation method is simple and quick, does not require expensive instruments and equipment, is economical and practical, and has broad application prospects in the preservation and transportation of urine.

[0153] The applicant declares that the above is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Those skilled in the art should understand that any changes or substitutions that can be easily thought of by those skilled in the art within the technical scope disclosed by the present invention shall fall within the protection scope and disclosure scope of the present invention.

Claims

1. A urine preservation solution, characterized in that: Taking the mass percentage as 100%, the urine preservation solution includes 0.01%-0.1% diethyl pyrocarbonate, 3%-7% ethylenediaminetetraacetic acid, 1%-5% imidazolidinyl urea, 2%-5% sulfite, 1%-5% sodium azide and 0.5%-2.5% spermidine, and the balance is water.

2. Use of the urine preservation solution as claimed in claim 1 in inhibiting microbial growth and / or nucleic acid degradation in urine.

3. A method for preserving urine, characterized in that: The method for preserving urine comprises concentrating the urine to be tested to obtain a precipitate, and mixing the precipitate with the urine preserving solution of claim 1 to obtain a mixed solution.

4. The method for preserving urine according to claim 3, characterized in that: The concentration comprises performing a first centrifugation on the urine to be tested, taking out the supernatant, performing a second centrifugation, and retaining the precipitate.

5. The method for preserving urine according to claim 4, characterized in that: The first centrifugation time is 1-5 min, and the first centrifugation speed is 1000-2000 r / min; The time of the second centrifugation is 5-15 min, and the speed of the second centrifugation is 10000-20000 r / min.

6. The method for preserving urine according to claim 3, characterized in that: The volume ratio of the precipitate to the urine to be tested is 1:(5-15); During the mixing, the volume ratio of the precipitate to the urine preservation solution is 1:(3-7).

7. The method for preserving urine according to claim 3, characterized in that: The mixing step also includes the steps of shaking and mixing and resuspending the precipitate.

8. The method for preserving urine according to claim 3, characterized in that: The storage temperature of the mixed solution is 0-8°C.

9. The method for preserving urine according to claim 3, characterized in that: The method for preserving urine comprises the following steps: (1) centrifuging the urine to be tested at 1000-2000 r / min for 1-5 min, taking the supernatant and centrifuging at 10000-20000 r / min for 5-15 min, retaining the precipitate, wherein the volume ratio of the precipitate to the urine to be tested is 1:(5-15); (2) Mix the precipitate with the urine preservation solution of claim 1, wherein the volume ratio of the precipitate to the urine preservation solution is 1:(3-7), shake and mix, resuspend the precipitate, obtain a mixed solution, and store it at 0-8°C.

10. Use of the urine preservation solution according to claim 1 or the method for preserving urine according to any one of claims 3 to 9 in detecting urine microbial content.